BindingDB logo
myBDB logout

202 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
26125514 40 Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human▀3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.EBI Asahi Kasei Pharma Corporation
25065493 92 The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting▀2-adrenoceptor agonist.EBI Novartis Institutes for BioMedical Research
24835980 98 Discovery of TD-4306, a long-acting▀2-agonist for the treatment of asthma and COPD.EBI Theravance, Inc.
24813741 110 Multivalent design of long-acting▀(2)-adrenoceptor agonists incorporating biarylamines.EBI Theravance, Inc.
16640337 47 Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.EBI GlaxoSmithKline
23614528 121 Synthesis and in vitro and in vivo characterization of highlyß1-selectiveß-adrenoceptor partial agonists.EBI University of Nottingham
23614494 2 Structure-based fragment screening is demonstrated to be a practical lead discovery method for a representative G-protein-coupled receptor.EBI Pfizer Inc.
23517028 2 Biophysical fragment screening of theß1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.EBI Heptares Therapeutics Ltd.
21870877 119 Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for humanß-adrenoceptors.EBI University of Nottingham
17507221 58 Identification and SAR of potent and selective non-peptide obeline somatostatin sst1 receptor antagonists.EBI Novartis Institutes for BioMedical Research
16759089 5 Role of Tyr(356(7.43)) and Ser(190(4.57)) in antagonist binding in the rat beta1-adrenergic receptor.EBI The University of Melbourne
11806709 63 Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.EBI GlaxoSmithKline
22932315 28 An investigation into the structure-activity relationships associated with the systematic modification of theß(2)-adrenoceptor agonist indacaterol.EBI Novartis Institutes for BioMedical Research
22079756 219 From libraries to candidate: the discovery of new ultra long-acting dibasicß2-adrenoceptor agonists.EBI AstraZeneca
22178551 46 A multivalent approach to the discovery of long-actingß(2)-adrenoceptor agonists for the treatment of asthma and COPD.EBI Theravance, Inc.
21925889 48 The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating a urea group.EBI GlaxoSmithKline Medicines Research Centre
21696967 51 The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating hydantoin or uracil rings.EBI GlaxoSmithKline Medicines Research Centre
21723724 91 Design-driven LO: the discovery of new ultra long acting dibasicß2-adrenoceptor agonists.EBI AstraZeneca
20462258 50 Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.EBI GlaxoSmithKline Medicines Research Centre
19317397 62 Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.EBI GlaxoSmithKline Medicines Research Centre
10737740 57 Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.EBI Freie Universit£t Berlin
9548813 53 The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.EBI SmithKline Beecham Pharmaceuticals
1361581 11 Computer-aided mapping of the beta-adrenoceptor. 1. Explanation for effect of para substitution on blocking activity at the beta-1-adrenoceptor.EBI University of Melbourne
1956038 21 Synthesis and ocular antihypertensive activity of new imidazolidine derivatives containing a beta-blocking side chain.EBI Institut de Pharmacologie (UA 589 CNRS)
2903245 47 Synthesis and beta-adrenergic antagonism of 2-(aryloxy)-1-(2-piperidyl)ethanols.EBI Universidad de Barcelona
2884312 39 Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.EBI TBA
2882026 21 Role of the (acyloxy)methyl moiety in eliciting the adrenergic beta-blocking activity of 3-(acyloxy)propanolamines.EBI TBA
2872332 105 Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted amino)-2-hydroxypropoxy]phenyl]imidazole class. 2.EBI TBA
3012084 7 Indole-phenol bioisosterism. Synthesis and antihypertensive activity of a pyrrolo analogue of labetalol.EBI TBA
2861288 17 New chiral and isomeric cyclopropyl ketoxime propanolamine derivatives with potent beta-adrenergic blocking properties.EBI TBA
2857200 24 An interdisciplinary approach to the design of new structures active at the beta-adrenergic receptor. Aliphatic oxime ether derivatives.EBI TBA
6330358 6 The 3,4-catechol derivative of propranolol, a minor dihydroxylated metabolite.EBI TBA
6148422 36 Synthesis and beta-adrenergic blocking activity of new aliphatic and alicyclic oxime ethers.EBI TBA
6134834 54 Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.EBI TBA
6130154 68 Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.EBI TBA
6130153 66 Ultra-short-acting beta-adrenergic receptor blocking agents. 1. (Aryloxy)propanolamines containing esters in the nitrogen substituent.EBI TBA
6120237 15 2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.EBI TBA
6104730 47 Synthesis and beta-adrenergic blocking activity of new aliphatic oxime ethers.EBI TBA
21486038 177 Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.EBI H. Lundbeck A/S
22386241 46 Synthesis and pharmacological evaluation of carbamic acid 1-phenyl-3-(4-phenyl-piperazine-1-yl)-propyl ester derivatives as new analgesic agents.EBI SK Biopharmaceuticals
22313227 78 Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.EBI National Institute of Mental Health
21726069 98 Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.EBI University of Namur
21207959 69 Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.EBI National Institute of Mental Health
20875743 90 Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity relaEBI Pfizer Inc.
20931963 112 Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.EBI ASKA Pharmaceutical Co, Ltd
20684563 176 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.EBI H. Lundbeck A/S
20181479 177 Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.EBI Merck Research Laboratories
19963380 38 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.EBI Hunter College and the Graduate Center of the City University of New York
19608416 29 Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.EBI Astellas Pharma Inc
19581100 162 Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.EBI Astellas Pharma Inc.
19232786 72 Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.EBI Astellas Pharma Inc.
18651730 123 Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.EBI Astellas Pharma Inc
16562853 22 Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.EBI Tom's of Maine
18307290 97 Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.EBI Astellas Pharma Inc.
16451077 86 Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.EBI Pfizer Inc.
16198561 99 Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.EBI Novartis Institutes for BioMedical Research
15603933 28 Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.EBI Fujisawa Pharmaceutical Co. Ltd
12213075 70 Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).EBI Purdue University
11311069 64 (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists.EBI Wyeth-Ayerst Research
11585444 295 From hit to lead. Analyzing structure-profile relationships.EBI F-59000 Lille
7562902 114 Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.EBI SmithKline Beecham Pharmaceuticals
7658429 31 (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).EBI Abbott Laboratories
8254623 20 Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.EBI National Institute of Diabetes and Digestive and Kidney Diseases
8230093 21 Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.EBI Universit£ di Pisa
1313109 20 Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.EBI Universit£ di Pisa
1359141 47 Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines.EBI Merck Sharp and Dohme Research Laboratories
2319556 16 Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.EBI Berlex Laboratories
1976812 30 Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.EBI Berlex Laboratories
2845082 23 Syntheses and adrenergic activities of ring-fluorinated epinephrines.EBI National Institute of Diabetes
6126588 34 Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene.EBI TBA
15203136 37 (+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents.EBI Virginia Commonwealth University
21863888 9 Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-ß2-agonist for the treatment of chronic obstructive pulmonary disease.EBI Pfizer Inc.
21783363 10 Synthesis and in vitro evaluation of derivatives of theß¿?-adrenergic receptor antagonist HX-CH 44.EBI University of Toronto
20036561 39 Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.EBI Medical University of Lublin
21353541 25 Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective humanß3 adrenergic receptor agonists.EBI Merck Research Laboratories
21277205 26 Discovery of substituted phenyl urea derivatives as novel long-actingß2-adrenoreceptor agonists.EBI Rhône-Poulenc Rorer
20833036 221 Thienopyrimidines asß3-adrenoceptor agonists: hit-to-lead optimization.EBI 4SC AG
20812727 157 Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.EBI National Institute of Mental Health
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20655218 72 A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.EBI Novartis Institutes for BioMedical Research
20684592 83 Identification of potent and selective amidobipyridyl inhibitors of protein kinase D.EBI Novartis Institutes for BioMedical Research
20684591 89 Identification of orally available naphthyridine protein kinase D inhibitors.EBI Novartis Institutes for BioMedical Research
20620058 41 Smoothened antagonists for hair inhibition.EBI Pfizer Inc.
20591666 66 A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.EBI Università degli Studi di Milano
20434333 111 A vHTS approach for the identification of beta-adrenoceptor ligands.EBI 4SC AG
20384344 42 Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.EBI Meiji Seika Kaisha, Ltd.
20096576 41 Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
19646882 72 Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.EBI University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and the Informatics Institute of UMDNJ
19643607 26 Studies towards topical selective beta2-adrenoceptor agonists with a long duration of action.EBI Boehringer Ingelheim Pharma GmbH& Co. KG
19875286 44 Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists.EBI Boehringer Ingelheim Pharma GmbH& Co KG
19783143 65 Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.EBI Novartis Institutes for BioMedical Research
19492813 56 Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.EBI GlaxoSmithKline
19366244 138 Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.EBI Astellas Pharma Inc.
19362005 74 Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.EBI Astellas Pharma Inc
19131251 9 Preliminary evaluation of pharmacological properties of some xanthone derivatives.EBI Jagiellonian University Medical College
19081260 10 Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling.EBI Central Drug Research Institute
18752946 47 Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.EBI Astellas Pharma Inc.
18701276 97 Highly functionalized 7-azaindoles as selective PPAR gamma modulators.EBI Merck Research Laboratories
18656910 2 Facile radiosynthesis of fluorine-18 labeled beta-blockers. Synthesis, radiolabeling, and ex vivo biodistribution of [18F]-(2S and 2R)-1-(1-fluoropropan-2-ylamino)-3-(m-tolyloxy)propan-2-ol.EBI Centre for Addiction and Mental Health
18640038 74 Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.EBI Amgen Inc.
18599160 4 Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1.EBI Rzeszów University of Technology
18553954 126 Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.EBI Astellas Pharma Inc.
17911024 37 Potent oxindole based human beta3 adrenergic receptor agonists.EBI Lilly Research Laboratories
17804228 44 Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.EBI Lilly Research Laboratories
17632003 55 Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.EBI Pfizer Global Research and Development
17571866 49 Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.EBI National Institute of Mental Health
17533126 78 Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
17524641 69 3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.EBI GlaxoSmithKline
17506540 52 Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.EBI Medical University of Lublin
17303428 22 Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes.EBI Università degli Studi di Milano
16931005 21 Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.EBI Lilly Research Laboratories
16392798 46 Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.EBI Columbia University College of Physicians and Surgeons
16361098 70 Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.EBI F. Hoffmann-La Roche Ltd
15686912 35 Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety.EBI Dainippon Pharmaceutical Co., Ltd
15546708 35 Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives.EBI Dainippon Pharmaceutical Co., Ltd
15546707 60 Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring.EBI Dainippon Pharmaceutical Co., Ltd
14643338 118 Binding of beta-carbolines at 5-HT(2) serotonin receptors.EBI Virginia Commonwealth University
12798332 35 Cyclic amine sulfonamides as linkers in the design and synthesis of novel human beta(3) adrenergic receptor agonists.EBI Wyeth Research
12657269 52 Novel and potent human and rat beta3-adrenergic receptor agonists containing substituted 3-indolylalkylamines.EBI Dainippon Pharmaceutical Co., Ltd.
12361399 17 Homoazanicotine: a structure-affinity study for nicotinic acetylcholine (nACh) receptor binding.EBI Universita di Camerino
12270184 34 Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 2: arylethanolaminomethylpiperidines.EBI Wyeth Research
12270183 45 Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 1: aryloxypropanolaminomethylpiperidines.EBI Wyeth Research
11720857 35 4-Aminopiperidine ureas as potent selective agonists of the human beta(3)-adrenergic receptor.EBI Wyeth-Ayerst Research
11327605 27 New oxadiazolidinedione derivatives as potent and selective human beta3 agonists.EBI Wyeth-Ayerst Research
11277513 25 2,4-Thiazolidinediones as potent and selective human beta3 agonists.EBI Wyeth-Ayerst Research
11212115 72 Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties.EBI Merck Research Laboratories
11055339 59 Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists.EBI Merck Research Laboratories
11052788 33 Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.EBI Merck Research Laboratories
10999482 52 Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.EBI Merck Research Laboratories
10987429 69 Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore.EBI Merck Research Laboratories
10915043 69 Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.EBI Merck Research Laboratories
10888325 90 Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.EBI Merck Research Laboratories
10888324 48 Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.EBI Merck Research Laboratories
10780918 27 Syntheses of (R)- and (S)-2- and 6-fluoronorepinephrine and (R)- and (S)-2- and 6-fluoroepinephrine: effect of stereochemistry on fluorine-induced adrenergic selectivities.EBI National Institute of Diabetes and Digestive and Kidney Diseases
10743949 32 (1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents.EBI Università di Perugia
10406657 91 Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore.EBI Merck Research Laboratories
10360736 2 S1319: a novel beta2-andrenoceptor agonist from a marine sponge Dysidea sp.EBI Kirin Brewery Co., Ltd.
10340609 15 L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.EBI Merck Research Laboratories
10201842 69 Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides.EBI Merck Research Laboratories
10201841 47 Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.EBI Merck Research Laboratories
9876110 58 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602).EBI Centro de Investigación Grupo Ferrer
9873681 65 3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists.EBI Merck Research Laboratories
9873496 80 3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.EBI Merck Research Laboratories
9871717 72 Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist.EBI Merck Research Laboratories
9871716 93 Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor.EBI Merck Research Laboratories
9572886 38 Synthesis and adrenergic activity of a new series of N-aryl dicyclopropyl ketone oxime ethers: SAR and stereochemical aspects.EBI University of Grenoble
9379432 36 Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prEBI Abbott Laboratories
8093626 13 o-Chlorobenzenesulfonamidic derivatives of (aryloxy)propanolamines as beta-blocking/diuretic agents.EBI Università di Perugia
7910217 36 The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists.EBI Universitá di Pisa
2892936 10 Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.EBI Warner-Lambert Company
2875184 11 (5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.EBI TBA
2563296 38 A new series of tricyclic (aryloximino)propanolamines displaying very high selective beta 2-blocking properties.EBI Université de Nancy I
1672155 11 Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol.EBI National Institute of Diabetes
1652023 161 Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.EBI Abbott Laboratories
1354264 16 Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.EBI American Cyanamid Company
1347318 52 Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.EBI Berlex Laboratories
19337725 43 Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.BDB Case Western Reserve University
16915381 31 WAY-100635 is a potent dopamine D4 receptor agonist.BDB Purdue University
16352709 44 Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.BDB McGill University
15831442 46 Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.BDB Taisho Pharmaceutical Co., Ltd
15131245 89 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
14730417 62 Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.BDB Universität Würzburg
12784105 53 Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.BDB Case Western Reserve University
12761331 97 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.BDB Case Western Reserve University
12649361 779 L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.BDB Case Western Reserve University
12431845 85 Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.BDB Lilly Research Laboratories
12388666 301 Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.BDB Institut de Recherches Servier
12192085 52 Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.BDB Case Western Reserve University
12110997 380 In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.BDB Westfälische Wilhelms-Universitä Muenster,
11750183 29 Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.BDB Novartis Pharma
11750180 141 Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.BDB Lilly Research Laboratories
11512051 80 The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor.BDB Case Western Reserve University
11438309 51 The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.BDB Janssen Research Foundation
11356907 15 Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.BDB Institut de Recherches Servier
11082457 63 S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.BDB Centre de Recherches de Croissy
11082453 77 ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.BDB Abbott Laboratories
9454810 73 SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.BDB Sanofi Recherche
9225287 174 RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.BDB Roche Bioscience
9144661 24 BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats.BDB SmithKline Beecham Pharmaceuticals
8935801 586 Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.BDB Janssen Research Foundation
8788493 64 Novel discriminatory ligands for 5-HT2B receptors.BDB SmithKline Beecham Pharmaceuticals
8730737 23 Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety.BDB SmithKline Beecham Pharmaceuticals
8584042 40 BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex.BDB Boehringer Ingelheim Italia
8564196 35 Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo.BDB Syntex Discovery Research
8012715 38 GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor.BDB Glaxo Group Research Ltd.
7921604 16 The effects of SB 204070, a highly potent and selective 5-HT4 receptor antagonist, on guinea-pig distal colon.BDB SmithKline Beecham Pharmaceuticals
7915318 120 Biochemical and pharmacological characterization of high-affinity trimetoquinol analogs on guinea pig and human beta adrenergic receptor subtypes: evidence for partial agonism.BDB Ohio State University
2530094 94 The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.BDB Novo Industri A/S
1982626 30 Neurochemical profile of eltoprazine.BDB Duphar B.V.
1968985 56 Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.BDB Niigata College of Pharmacy
1661335 95 Receptor binding profiles of amiloride analogues provide no evidence for a link between receptors and the Na+/H+ exchanger, but indicate a common structure on receptor proteins.BDB Center for Bio-Pharmaceutical Sciences
15655528 75 The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.BDB University of Nottingham